作者:Zhu, Fuqiang、Zhang, Jian、Xiamuxi, Hainimu、Chen, Weiming、Hu, Tianwen、Yang, Xiaojun、Tian, Guanghui、Ni, Runyan、Li, Jian、Suo, Jin、Xie, Yuanchao、Shen, Jingshan、Aisa, Haji A.、He, Yang
DOI:10.1691/ph.2018.8059
日期:——
Impurities A–F were observed, identified, and confirmed during the efinaconazole production process. The possible formation pathways of the mentioned impurities were understood, and thereafter, a controlling strategy was established by locating the proper process parameters with the consideration of efficient cost and less waste as well. This impurity investigation is also essential for quality control of consistently delivering of qualified efinaconazole API.
在依芬康唑的生产过程中,对杂质 A-F 进行了观察、鉴定和确认。了解了上述杂质的可能形成途径,并在此基础上,通过确定适当的工艺参数,制定了控制策略,同时考虑到了高效成本和减少浪费。这项杂质调查对于持续提供合格的依芬康唑原料药的质量控制也至关重要。